At the March meeting of the Australian Pharmaceutial Benefits Advisory Committee (PBAC), approval for the two new CLL treatments, obinutuzimab (Gazyva®) and Idelalisib (Zydelig®) will be decided, namely:
1) To request Authority Required (STREAMLINED) listing of Idelalisib for the treatment of CLL in patients with progressive disease despite previous treatment.
2) To request Section 100 (Efficient Funding of Chemotherapy) listing of Obinutuzimab for the treatment of CLL.
If you have had prior therapy for CLL and you need treatment again fairly soon, then it is unlikely that you will benefit from a repeat of your earlier treatment. You really need access to an alternative treatment (such as Idelalisib) to gain any benefit.
As the PBAC site says:
"Your comments are welcome whether you are a patient, carer, member of the public, health professional or member of a consumer interest group."
You can support these submissions via on line comment to the PBAC.
On line submission - must be provided by 11th February:
Background information on consumer comments:
Background information on PBAC's role, Meeting Agenda and Consumer Comments:
March Meeting Agenda:
Section 100 (Efficient Funding of Chemotherapy):
For more information on these new drugs do a site search for obinutuzimab and Idelalisib.
Thanks for your support!